Adamis Pharmaceuticals Corporation Aktie News

Company to begin trading under new ticker symbol “DMK” on September 8, 2023 Company to begin trading under new ticker symbol “DMK” on September 8, 2023

SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) --  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.

SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock. Each unit was sold at a public off...

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the pricing of its public offering of 5,930,000 units at a public offering price of $1.35 per unit. Each unit consists of one share of common stock (or a prefunded warrant in lieu thereof) and one warrant to purchase one share of common s...

SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit. The funding will support the work of Albert Dahan, MD, PhD, a world expert on opioid-induced...

SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that its wholly owned subsidiary DMK Pharmaceuticals Corporation was the recipient of a grant from the National Institute on Alcohol Abuse And Alcoholism (NIAAA) of the National Institutes of Health (NIH) to support the development of a no...

SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that Eboo Versi, MD, PhD, CEO of Adamis Pharmaceuticals is proud and excited to have participated in the White House Roundtable with Opioid Reversal Product Manufacturers, hosted by White House Office of National Drug Control Policy Direct...

SAN DIEGO, May 25, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its merger with DMK Pharmaceuticals Corporation.